Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.

Solomon SR, Nakamura R, Read EJ, Leitman SF, Carter C, Childs R, Dunbar CE, Young NS, Barrett AJ.

Bone Marrow Transplant. 2003 May;31(9):783-8.

PMID:
12732885
2.

One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.

Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS, Fenu S, Moleti ML, De Felice L, Girelli G, Arcese W.

Haematologica. 2003 Mar;88(3):315-23.

3.

Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.

Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.

Bone Marrow Transplant. 1999 Mar;23(5):443-50.

5.

Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.

Hoyt R, Ritchie DS, Roberts AW, Macgregor L, Curtis DJ, Szer J, Grigg AP.

Bone Marrow Transplant. 2008 Apr;41(7):651-8. doi: 10.1038/sj.bmt.1705955. Epub 2008 Jan 7.

PMID:
18176619
6.

GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.

Olsson R, Remberger M, Hassan Z, Omazic B, Mattsson J, Ringdén O.

Eur J Haematol. 2010 Apr;84(4):323-31. doi: 10.1111/j.1600-0609.2009.01390.x. Epub 2009 Nov 30.

PMID:
20002156
7.

Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.

Baron F, Baudoux E, Frère P, Tourqui S, Schaaf-Lafontaine N, Greimers R, Herens C, Fillet G, Beguin Y.

J Hematother Stem Cell Res. 2002 Apr;11(2):301-14.

PMID:
11983101
8.
9.

Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.

Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G, Beguin Y.

Haematologica. 2002 Jan;87(1):78-88.

10.

[Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].

Zhang WP, Wang JM, Ju XP, Song XM, Tong SP, Li HM.

Zhonghua Xue Ye Xue Za Zhi. 2003 Mar;24(3):129-33. Chinese.

PMID:
12697123
11.

In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.

Nachbaur D, Eibl B, Kropshofer G, Meister B, Mitterschiffthaler A, Schennach H, Fischer G, Kopp M, Gunsilius E, Gastl G.

J Hematother Stem Cell Res. 2002 Aug;11(4):731-7.

PMID:
12201962
12.

Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.

Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.

Bone Marrow Transplant. 2003 Jan;31(2):121-8.

PMID:
12621494
13.

A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.

Guo M, Sun Z, Sun QY, Han Q, Yu CL, Wang DH, Qiao JH, Chen B, Sun WJ, Hu KX, Liu GX, Liu B, Zhao RC, Ai H.

Biol Blood Marrow Transplant. 2009 Aug;15(8):930-7. doi: 10.1016/j.bbmt.2009.04.006.

14.

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.

Ross M, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Forman SJ, Blume KG, Chao NJ.

Biol Blood Marrow Transplant. 1999;5(5):285-91.

PMID:
10534058
15.

Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.

Ferrá C, Rodríguez-Luaces M, Gallardo D, Encuentra M, Martín-Henao GA, Peris J, Ancín I, Sarrá J, Berlanga JJ, García J, Grañena A.

Bone Marrow Transplant. 2001 Nov;28(10):963-8.

16.

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.

Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ.

Bone Marrow Transplant. 1998 Mar;21(6):543-51.

18.

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.

Blood. 2001 Aug 15;98(4):934-9.

19.

High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease.

Schwinghammer TL, Bloom EJ, Rosenfeld CS, Wilson JW, Przepiorka D, Shadduck RK.

Bone Marrow Transplant. 1995 Jul;16(1):147-54.

PMID:
7581115
20.

Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.

Takami A, Okumura H, Yamazaki H, Kami M, Kim SW, Asakura H, Endo T, Nishio M, Minauchi K, Kumano K, Sugimori N, Mori S, Takemoto Y, Shimadoi S, Ozaki J, Takaue Y, Nakao S.

Int J Hematol. 2005 Dec;82(5):449-55.

PMID:
16533751
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk